Latest / Columbus' Morning News / Weight-Loss Drugs and Blindness
Transcript
- 0:00Speaker 1: Thank you for jumping on board with us this morning.
- 0:01Speaker 1: Eight minutes after seven Friday. It's Mike Elliott, Columbus's morning news.
- 0:05Speaker 1: Starting to see some rain move in and it'll be
- 0:08Speaker 1: with us most of the morning and midday. So if
- 0:10Speaker 1: you are getting ready to jump out and or you're
- 0:12Speaker 1: in the car now and just getting going, make sure
- 0:14Speaker 1: you maybe save a couple extra minutes because people can't
- 0:18Speaker 1: drive in Columbus when it rains. They just can't. And
- 0:22Speaker 1: just take your time and we'll get with Johnny Hill
- 0:24Speaker 1: and update your traffic and weather together on the way.
- 0:28Speaker 1: How about the Blue Jack? What a start for Matthew Nyes.
- 0:33Speaker 1: He's only been in Columbus for, what, five days? Four days?
- 0:37Speaker 2: Yeah.
- 0:37Speaker 1: Two goals and an assist last night in the win
- 0:39Speaker 1: over Buffalo, 6-3. Have a day, buddy. No doubt. I mean,
- 0:43Speaker 1: you want to talk about selling some No. 89 Nyes jerseys.
- 0:47Speaker 1: I'm guessing he sold a couple last night. Are they
- 0:50Speaker 1: going to have the new– is the new logo going
- 0:52Speaker 1: to be, that's a Nyes jersey? That's a Nyes jersey.
- 0:57Speaker 1: It's not just a Blue Jackets jersey. That's a nice jersey.
- 1:01Speaker 1: Come on, man. Nice game, Matthew. I get the patent
- 1:04Speaker 1: on that. Nice game, Matthew. You should get the patent
- 1:08Speaker 1: on that.
- 1:08Speaker 2: That's a nice jersey.
- 1:10Speaker 1: But the players who you want to be on the
- 1:12Speaker 1: score sheet were on the score sheet. Cole Sillinger got
- 1:14Speaker 1: the first one.
- 1:15Speaker 2: Yep.
- 1:16Speaker 1: He got us off to a good start. Adam Fantilli scored.
- 1:19Speaker 2: Atta boy.
- 1:20Speaker 1: Nyes got two. Sean Monaghan, who's the second line center,
- 1:23Speaker 1: he scored. Matthew Olivier scored. He's on the third line.
- 1:26Speaker 1: Which guarantees you a victory right there. I mean, late
- 1:29Speaker 1: last season, when the Jackets went on a little bit
- 1:31Speaker 1: of a run and they were, every time that That
- 1:34Speaker 1: Matthew Olivier scored, the Jackets won. I felt like we
- 1:37Speaker 1: came on every other day. There was like, Olivier, another score.
- 1:40Speaker 1: Jackets win. Olivier scores.
- 1:42Speaker 2: Right.
- 1:43Speaker 1: So, Nye is quickly becoming a fan favorite in Columbus.
- 1:46Speaker 1: It's a Nye's jersey. And it'll be a Nye's night
- 1:49Speaker 1: tomorrow at Nationwide. It'll be a Nye's night. That's right.
- 1:51Speaker 1: As the Jackets host the Utah, was it the Utah Mammoth? God,
- 1:55Speaker 1: I almost forgot they existed. I know. They're the latest
- 1:59Speaker 1: expansion team. That's gone extinct, too. Matt, the Utah Mammoth. Bro,
- 2:04Speaker 1: I can't talk about the Browns without laughing.
- 2:06Speaker 2: Stop it.
- 2:07Speaker 1: Come on. They get the win. It's just so funny.
- 2:11Speaker 1: Over the summer, you're trashing Deshaun Watson. He's garbage. Worst
- 2:16Speaker 1: deal ever. He hasn't played in 22 months. The Browns
- 2:21Speaker 1: can't get out of their own way. Now it's like, yes,
- 2:24Speaker 1: he's our guy. He's the man. Knew it all along.
- 2:27Speaker 1: They get the win in the late drive. They came
- 2:31Speaker 1: down with about a minute or so left, 80-yard drive,
- 2:36Speaker 1: after the Steelers tied it up and they kicked a
- 2:39Speaker 1: 56-yard field goal with 10 seconds left to get the win.
- 2:43Speaker 1: And Browns fans enjoying a weekend. Absolutely. All right, let's
- 2:47Speaker 1: go to the LegacyRetirementGroup.com phone line. This is pretty interesting.
- 2:50Speaker 1: Let's check in with Dr. Joe Gulati. You can find
- 2:52Speaker 1: him at DrJoeGulati.com. GLP-1 drugs everywhere and a lot of
- 2:59Speaker 1: options there. And there's a new study, Doc, that says
- 3:01Speaker 1: there is a risk of blindness for patients taking some
- 3:05Speaker 1: of the GLP-1 drugs. What's the story?
- 3:07Speaker 2: Well, you know, really what triggered this is that we've
- 3:10Speaker 2: known about this problem, albeit very rare, but a lawsuit
- 3:13Speaker 2: came up. And any time you have a lawsuit... especially
- 3:16Speaker 2: in sort of a drug-related issue, it's going to get attention.
- 3:20Speaker 2: There's a very, very rare complication. This is really a mouthful.
- 3:24Speaker 2: Non-arteretic anterior ischemic optic neuropathy. Wow. N-A-I-O-N. I know.
- 3:30Speaker 1: I mean, I can't even say.
- 3:31Speaker 2: It myself on a Friday morning. But anyway, what happens
- 3:34Speaker 2: is this results in sudden painless blindness, and sometimes it's
- 3:40Speaker 2: going to be permanent. Now, With the lawsuit, of course,
- 3:43Speaker 2: you're going to have some patients that have been on
- 3:45Speaker 2: the GLP-1 for weight loss and control of diabetes, and
- 3:49Speaker 2: they're coming up with this, and it's going to trigger
- 3:51Speaker 2: a lawsuit. Now, the true issue here is that there
- 3:56Speaker 2: really is not enough data to say it's the GLP-1.
- 4:01Speaker 2: This condition, albeit very rare, can occur even if you're
- 4:05Speaker 2: not taking a GLP-1. So there isn't enough support to
- 4:09Speaker 2: really say this is a definite complication. The FDA, which
- 4:14Speaker 2: is usually pretty conservative, they're not ready to weigh in
- 4:18Speaker 2: on this. And it only occurs in about 2 in 10,000
- 4:23Speaker 2: people on the GLP drug. So it's a very rare complication.
- 4:27Speaker 2: But again, you never want to see it. And we'll
- 4:29Speaker 2: see how the lawsuit plays out against the manufacturers against
- 4:33Speaker 2: these drugs.
- 4:34Speaker 1: I'm not going to try to repeat the actual name
- 4:36Speaker 1: of the condition, but what I'm seeing is it's described
- 4:40Speaker 1: as a stroke of the optic nerve when blood flow
- 4:43Speaker 1: to the optic nerve is reduced. And again, as you
- 4:47Speaker 1: point out, it's very rare. Are there, like, any underlying
- 4:51Speaker 1: conditions that people that they're maybe drawing a connection to,
- 4:55Speaker 1: like folks who maybe have type 2 or high blood
- 4:57Speaker 1: pressure or who are obese?
- 5:00Speaker 2: Yeah, well, you know, that's a very good point because, look,
- 5:02Speaker 2: we know that diabetes, hypertension, high cholesterol, cardiovascular disease leads
- 5:08Speaker 2: to eye problems, okay? We know that diabetics have the
- 5:11Speaker 2: risk of going blind. So there may be this connection
- 5:14Speaker 2: that the mere fact that you're overweight and have these
- 5:17Speaker 2: metabolic issues is you're at risk for eye and retina problems.
- 5:21Speaker 2: The other thing is, which I think is a very
- 5:24Speaker 2: good thing, the ophthalmology physicians have come out to say
- 5:31Speaker 2: any physician starting a GLP-1 drug should have a dedicated
- 5:38Speaker 2: retinal examination and eye examination before you start these drugs
- 5:41Speaker 2: to make sure that you don't have any other eye
- 5:44Speaker 2: pathology sitting there that you may not know. So, again,
- 5:47Speaker 2: I think the big question is, is this a big risk?
- 5:50Speaker 2: I think it's a very small risk, but we have
- 5:53Speaker 2: to look at the benefit of these drugs as much
- 5:56Speaker 2: greater than the small risk. But everybody has to go
- 5:59Speaker 2: into it as an informed consumer to say this could
- 6:03Speaker 2: be a complication and really proceed with caution.